About the Authors
- Sheyu Li
-
Contributed equally to this work with: Sheyu Li, Qianrui Li
Affiliation Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, 610041, China
- Qianrui Li
-
Contributed equally to this work with: Sheyu Li, Qianrui Li
Affiliation Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, 610041, China
- Yun Li
-
Affiliation Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, 610041, China
- Ling Li
-
Affiliation Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, 610041, China
- Haoming Tian
-
* E-mail: hmtian999@126.com (HT); sunx79@hotmail.com (XS)
Affiliation Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, 610041, China
- Xin Sun
-
* E-mail: hmtian999@126.com (HT); sunx79@hotmail.com (XS)
Affiliation Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, 610041, China
Competing Interests
Dr. Haoming Tian had worked as principal investigator of the phase III clinical trial of acetyl-L-carnitine tablet produced by Haisco Pharmaceutical China, which had however no relationship with the current meta-analysis. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: SL QL HT XS. Performed the experiments: SL QL YL. Analyzed the data: SL QL LL. Wrote the paper: SL QL.